comparemela.com

Latest Breaking News On - National key laboratory of translational medicine - Page 1 : comparemela.com

SIMCERE PHARMA (HK 2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China - Press Release

HONG KONG, May 17, 2022 /PRNewswire/ SIMCERE PHARMA (HK.2096) announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company h

Simcere pharmaceutical groupNational medical products administrationInnovative drug developmentShanghai institute of materia medicaNational key laboratory of translational medicineWuhan institute of virologyChinese academy of sciencesShanghai instituteMateria medicaWuhan instituteChinese academyClinical trial approvalShandong provincial qianfoshanPharmaceutical groupNational key laboratoryTranslational medicine

Simcere: SIMCERE PHARMA (HK 2096) to host 2022 R&D Day

HONG KONG, April 7, 2022 /PRNewswire/ SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of "providing today's patients with medicines of the future"

Ekevin oliverRen jinshengJason baoDanny chenBijoyesh mookerjeeSimcere pharmaceutical groupInnovative drug developmentNational key laboratory of translational medicineZhou gaoboTang renhongPharmaceutical groupNational key laboratoryTranslational medicineInnovative drug

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

/PRNewswire/ On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and.

Jinsheng renLynk pharmaceuticals co ltdSimcere pharmaceutical groupLynk pharmaceuticalsInnovative drug developmentNational key laboratory of translational medicinePharmaceutical groupNational key laboratoryTranslational medicineInnovative drug

vimarsana © 2020. All Rights Reserved.